Navigation Links
Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

NEW HAVEN, Conn., Nov. 3 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today that Susan Froshauer, PhD, President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 2:00pm EST. The conference will be held from November 10-12, 2008 at the Palace Hotel, New York, NY.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. Radezolid (RX-1741), an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococus pneumonia and S. pyogenes. Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active against a broad spectrum of bacteria, including quinolone-resistant Gram-positive bacteria and MRSA. Both radezolid and delafloxacin are currently in Phase 2 clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at http://www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Womens Hall of Fame
2. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
5. DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc.
6. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
7. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
8. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
9. Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent
10. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
11. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... Garland, TX (PRWEB) , ... February 10, 2016 ... ... the commencement of a master charity program created to assist the local community. ... closely with community leaders and nonprofit organizations in the area. Their goal is ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental ... dental patients and families in the North Metro Denver area. The new dental practice ... cosmetic dentistry, and all in the most relaxing environment. , While some dental visits ...
(Date:2/10/2016)... ... February 10, 2016 , ... Gout is like no other joint pain. It ... severe, with intense swelling and redness. It is triggered by the crystallization of uric ... are the most susceptible, according to the February 2016 issue of Harvard Men's Health ...
(Date:2/10/2016)... Boston, Massachusetts (PRWEB) , ... February 10, 2016 ... ... practice models to effectively measure change in their patients. Research shows that the ... traditional methods. To help therapists overcome this challenge and learn more about the ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Oxis International Inc. (OTC/QB: OXIS) announced today that ... a "clinical trial triumph" after one of the first ... remission. Daniel Vallera , a research ... --> Daniel Vallera , a research ... --> An article on the University ...
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... AKIVA, Israel , February 10, 2016 ... a leader in the field of cartilage repair, announces ... February 5, 2016. The $15 million investment was led ... Chinese pharmaceutical manufacturer, and was joined by existing Regentis ... Holdings and both the Technion Research & Development Foundation ...
Breaking Medicine Technology: